Skip to content

Change in receivables at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$13.1M-1,256%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$7.72M+103%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$474K-96.6%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's change in receivables?
Arbutus Biopharma Corporation (ABUS) reported change in receivables of $178.74M in Q1 2026.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.